Oncology and Biotech

Selected news for the healthcare topic - Oncology, and the healthcare topic - Biotech. We have 2,660 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/5/2022 Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module ... biotech company specialized in next generation antibody therapies, announced today that they have entered into a collaboration to develop next-generation antibody therapies. Junshi Biosciences will obtain the license to one of DotBio‚Aos DotBody modules, to be used within the oncology field for the development of several multi-specific antibodies. DotBio will be entitled to upfront and milestone payments, as well as royalties as the molecules progress through clinical ...
12/29/2021 28 Startups Biotech's Top VC Arch Venture Is Investing in Next Business Insider Insider analyzed more than 90 IPOs to find the top venture-capital firms that led biotech in 2021 . Arch Venture Partners topped the list, holding nearly $2 billion in equity in biotechs that IPO'd. Take ... latest fund to invest in several hot fields ‚Ai including oncology, immunology, and genetics ‚Ai while lending the venture-capital firm's capital and credentials to fields that have been placed in the spotlight during the ...
12/15/2021 China's BeiGene Shares Plunge in Shanghai Debut Beijing-based biotechnology company develops and commercialises immune-oncology and molecularly-targeted cancer treatment drugsChinese biotech company BeiGene plunged on its Shanghai debut on Wednesday after raising $3.5 billion in the biggest STAR Market listing this year.BeiGene, which has posted consecutive years of losses, tumbled more than 15% in early trading, after opening 8.1% lower than its offer price of 192.6 yuan.Founded in 2010, BeiGene is a ...
12/8/2021 The Ridgway Record SAN DIEGO, CA 7, 2021 / Ainos, Inc. ("we", "our", or the "company"), (OTC PINK:AIMD), a diversified healthcare company engaged in the discovery and development of pharmaceutical, medical devices and biotech products announced it entered into a Development and Sales Agreement with InnoPharmax, Inc. ("InnoPharmax"), a specialty pharmaceutical company focused in the development and commercialization of products for the treatment of infectious diseases, immunology, and oncology.Ainos and InnoPharmax agreed ...
12/7/2021 8 Most Volatile Penny Stocks ... Biotech, Inc.- Celyad Oncology SA- Advanced Human Imaging Ltd.Most Volatile Penny Stocks to Buy NowUcommune InternationalUcommune is a volatile penny stock that provides office space to other businesses. The company also provides marketing, branding and other services.Ucommune works in China. And focuses primarily on creating office spaces. It has expertise in real estate. In addition to seeking out old buildings and those that aren‚Aot used ...
12/6/2021 Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer | Financial Buzz ... Oncology (Nasdaq:PYXS) and previous roles at Longwood Fund and PureTech Health, where he co-founded and helped to build multiple biotech and life sciences companies. In his role at Arrakis, he will be responsible for leading corporate strategy, business development, investor relations and finance as Arrakis enters its next stage of growth, advancing its pipeline of wholly owned and partnered programs toward the clinic.This press release features multimedia ...
11/30/2021 Scientist/Senior Scientist ‚Äì Sorrento Therapeutics ‚Äì San Diego, CA ... and possibly curable diseases. Sorrento‚Aos multimodal multipronged approach to fighting cancer is made possible by its‚Ao extensive immuno-oncology platforms, including key assets such as fully human antibodies (‚AuG-MAB‚N¢ library‚Au ... If you‚Aore a quick learner, enjoy working in the biotech industry, and share our mission of providing ground-breaking impact to medicine, each other, and our patients, Sorrento Therapeutics is the place for you ...
10/13/2021 IMF's Gita Gopinath on economic outlook; William Shatner to launch into space on Blue Origin flight AYahoo Finance‚Aos Brian Sozzi and Julie Hyman speak with Christiana Bardon, BioImpact Capital Co-Managing Partner, about MPM Capital‚Aos second Oncology Impact Fund, and outlook for the biotech space. Klarna CEO Sebastian Siemiatkowski joins Yahoo Finance‚Aos Julie Hyman and Aarthi Swaminathan to discuss the company‚Aos latest partnership with Simon Property Group, as well as the future of the buy now pay later landscape. Gita Gopinath, Economic ...
10/7/2021 Immunicom Hires Former FDA Clinician and Medical Device Reviewer to Rapidly Progress Launch of Novel Cancer Immunotherapy Yahoo News ... biotech pioneering non-pharmaceutical immunotherapies, hires Dr. Christian Shenouda as Vice President of Regulatory Affairs to develop and execute regulatory strategy to integrate the Immunopheresis ¬Æ therapy into standard medical practice. Immunicom expects streamlined regulatory approval for the Immunopheresis therapy under the expertise of Dr. Shenouda alongside Immunicom‚Aos three ongoing clinical oncology trials. The addition of Dr. Shenouda to the Immunicom team strengthens plans to advance FDA regulatory interaction ...
10/7/2021 HPAPIs and Cytotoxic Drugs Manufacturing Market Demands and Growth Prediction 2018 to 2026 ... biotech companies, in order to treat cancer. For instance, new immuno-oncology therapies such as antibody-drug conjugates are manufactured through HPAPIs manufacturing companies. Increasing mortality due to cancer is expected to be a factor for growth of the market. According to World Health Organization, 2018, cancer is one of the leading causes of morbidity and mortality worldwide, with around 14 million new cases in 2012 and accounted for death ...
10/6/2021 Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R FierceBiotech Arch Venture Partners has taken the lid off its big bet on neuroscience. Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics‚Aia biotech that starts life with $500 million, a collaboration with Amgen and a pipeline of eight prospects. Neumora represents a test of the idea that neuroscience is on the cusp of the sort of rapid progress that has transformed oncology ...
10/6/2021 Roswell Biotechnologies Appoints Biotech Veteran Mike Aicher as Executive Chairman of Board of Directors PR Newswire SAN DIEGO Roswell Biotechnologies, Inc ., the molecular electronics company, announced today the appointment of Mike Aicher as executive chairman of its board of directors. A biotech industry veteran and entrepreneur, Mr. Aicher brings a wealth ... molecular diagnostics solutions, chairman of CytoBay, a company developing novel oncology solutions, and serves on the board of directors for Techcyte, a company providing artificial intelligence-powered diagnostic solutions. He previously served on the board ...
10/5/2021 High Potency APIs /HPAPI Market worth 26.84 Billion USD by 2023 ‚Äì Exclusive Report by MarketsandMarkets‚Ñ¢ High Potency APIs /HPAPI Market worth 26.84 Billion USD by 2023 ‚Ai Exclusive Report by MarketsandMarkets‚N¢ PUNE, India, 2021-Oct-05 ‚Ai /EPR Network/ ‚Ai According to the new market research report, ‚Au High Potency APIs /HPAPI Market by Type (Innovative, Generic), Synthesis (Synthetic, Biotech, moAB, Vaccines, Recombinant Proteins), Manufacturer (Captive and Merchant), Therapy (Oncology, Glaucoma, Hormonal Imbalance) ‚Ai Global Forecasts to 2023‚A≥, The Global HPAPIs Market is ...
10/3/2021 Brooks Group Announces 5 Star Excellence in Oncology Account Management The Brooks Group is announcing a three-day immersive training event for oncology account managers designed to improve client relations and enhance the skills necessary to become a Trusted Advisor.WEST CHESTER, PA, The Brooks Group, a leader in training programs across the pharmaceutical and biotech industries which are designed to enhance performance and outcomes for both executives and account management personnel. The organization is pleased to announce a new ...
10/3/2021 Brooks Group Announces 5 Star Excellence in Oncology Account Management WEST CHESTER, PA, October 03, 2021 /24-7PressRelease/ -- The Brooks Group, a leader in training programs across the pharmaceutical and biotech industries which are designed to enhance performance and outcomes for both executives and account management personnel. The organization is pleased to announce a new training event. An Immersive Learning Environment The Excellence in Oncology Account Management event is designed to provide current and aspiring account managers with critical tools that ...
10/1/2021 The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30) - Biohaven Pharmaceutical ... CNSP] ) - Cue Health Inc. (NASDAQ: [HLTH] ) (IPOed Sept. 24) - Cullinan Oncology, Inc. (NASDAQ: [CGEM] ) - Eiger BioPharmaceuticals, Inc. (NASDAQ: [EIGR] ) - Eledon Pharmaceuticals, Inc. (NASDAQ: [ELDN] ) - Emergent BioSolutions Inc. (NYSE: [EBS] ) - First Wave BioPharma, Inc. (NASDAQ: [FWBI ...
9/30/2021 BioNTech vs. Moderna: Which Vaccine Stock is a Better Buy? post] was originally published on [this site] BioNTech SE ( BNTX ) develops and commercializes immunotherapies for cancer and other infectious diseases. On the other hand, Moderna ( MRNA ) develops therapeutics and vaccines based on messenger RNA to treat infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. The biotech industry thrived amid the pandemic due to substantial capital inflows to develop an effective vaccine to contain the spread of ...
9/30/2021 Biotech incubator Sporos' new CEO arrives from Ovid with Biogen, Bristol Myers experience | FierceBiotech FierceBiotech ... venture after leaving Ovid Therapeutics last month following a lead therapy failure in April. His next stop is leading Houston biotech incubator Sporos Bioventures.Rakhit hit the exit at Ovid as president and chief medical ... other companies under Sporos' wings are cancer fibroblast biotech Stellanova , oncology biotech Nirogy and cancer immunotherapy startup Asylia Therapeutics .Sporos is also led by former Genzyme CFO Michael Wyzga and Chief Scientific Officer Jeno Gyuris ...
9/30/2021 Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement Business Wire ... biotech companies to join the over 15,000 companies across 100 countries that have committed to philanthropic efforts through Pledge 1%. Artiva is an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer. In addition to its efforts to develop innovative technologies designed to deliver safe and accessible therapies to cancer patients, by joining the Pledge 1%, Artiva is demonstrating its commitment to ...
9/30/2021 IMPACT Therapeutics Appoints Chun-Pyn Shen as Head of Regulatory Affairs ... in bio-pharmaceutical industry and academic research. Before joining IMPACTTherapeutics, he served as Vice President, Global Project Head in DymaniCure Biotechnology. He has a broad experience in regulatory affairs and pharmaceutical R&D, started his ... contribution to the approval of BAVENCIO® (avelumab) for multiple oncology indications in US. Then he served as the RA Head and strategy consultant to CEO at Hengenix Biotech (an affiliate of Shanghai Henlius Biotech ...
9/30/2021 Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement | Financial Buzz ... biotech companies to join the over 15,000 companies across 100 countries that have committed to philanthropic efforts through Pledge 1%.Artiva is an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer. In addition to its efforts to develop innovative technologies designed to deliver safe and accessible therapies to cancer patients, by joining the Pledge 1%, Artiva is demonstrating its commitment to ...
9/30/2021 IMPACT Therapeutics Appoints Dr. Chun-Pyn Shen as Head of Regulatory Affairs PR Newswire ... bio-pharmaceutical industry and academic research. Before joining IMPACT Therapeutics, he served as Vice President, Global Project Head in DymaniCure Biotechnology. He has a broad experience in regulatory affairs and pharmaceutical R&D, started his ... contribution to the approval of BAVENCIO® (avelumab) for multiple oncology indications in US. Then he served as the RA Head and strategy consultant to CEO at Hengenix Biotech (an affiliate of Shanghai Henlius Biotech ...
9/29/2021 Can These Former Biotech Growth Stocks Regain Their Form? Biotech investing is a tumultuous process. Equities can stagnate for years while the multi-phase clinical process unfolds. And then, seemingly out of the blue, their share prices can explode higher following a positive trial ... clinical, or regulatory setback.Acadia Pharmaceuticals ( NASDAQ:ACAD ) and Clovis Oncology ( NASDAQ:CLVS ) have both lagged behind the broader markets in a big way in 2021, even though they were super-charged growth stocks in ...
9/29/2021 Anji Pharma adds $70M for clinical trials, expansion of ‘hub and spoke’ biz model - MedCity News MedCity News Anji Pharma, a biotech with outposts in China and the U.S., has raised $70 million to continue clinical development of two metabolic disorder drugs and begin work on an oncology pipeline.The cash infusion, a Series B round of financing, was provided entirely by China-based CR Capital, a firm that invests in biotech companies in the U.S. and China with a goal of facilitating cross-border business opportunities. Anji ...
9/29/2021 NOXXON to Participate in Biotech and Health-Tech Conferences in October 2021 Yahoo News BERLIN, September 29, 2021 --( BUSINESS WIRE )--Regulatory News:NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) , a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces that Aram Mangasarian, CEO of ... event organized by the Sachs Associates. The session entitled " Immuno-Oncology BD&L Panel " is scheduled on Friday, October 8, 2021 at 11:20 a.m. CEST and will be chaired by speakers from Locust Walk and ...